Obseva (OBSV) Receives Buy Rating from Credit Suisse Group
Credit Suisse Group reaffirmed their buy rating on shares of Obseva (NASDAQ:OBSV) in a report released on Tuesday, Marketbeat reports. Credit Suisse Group currently has a $18.00 price target on the stock, up from their previous price target of $16.00.
OBSV has been the topic of several other research reports. HC Wainwright reissued a buy rating and set a $25.00 price objective on shares of Obseva in a report on Wednesday, November 8th. Royal Bank of Canada reissued a buy rating and set a $22.00 price objective on shares of Obseva in a report on Thursday, November 2nd. BMO Capital Markets began coverage on Obseva in a report on Monday, December 4th. They set an outperform rating and a $20.00 price objective on the stock. Finally, Zacks Investment Research lowered Obseva from a buy rating to a hold rating in a report on Tuesday, December 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $19.67.
Shares of Obseva (NASDAQ:OBSV) opened at $14.30 on Tuesday. Obseva has a fifty-two week low of $5.00 and a fifty-two week high of $15.81.
COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.dailypolitical.com/2018/03/03/obseva-obsv-receives-buy-rating-from-credit-suisse-group.html.
Obseva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.